Detecting and preventing the cardiovascular harm that can accompany cancer treatment.

Cardiovascular Toxicity Prevention
Research Area Overview
Many cancer therapies, from anthracyclines to immune checkpoint inhibitors, carry a risk of cardiovascular toxicity. This research area focuses on identifying that risk early and intervening before lasting damage occurs, so patients can complete their cancer treatment safely and with confidence.

Related Publications
Get in Touch
Interested in collaborating with us or learning more about our clinical and research program? We’d love to hear from you.
